Ontology highlight
ABSTRACT: Importance
Extended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance access, alleviate patient and health system financial toxicity, and improve patient quality of life, particularly during the COVID-19 pandemic. Neither adoption nor effectiveness of extended interval in the US has been adequately described.Objective
To describe adoption of extended-interval dosing of pembrolizumab since its FDA approval and to measure its preliminary real-world effectiveness compared with standard-interval dosing.Design, setting, and participants
This was a retrospective cohort study that used data from
SUBMITTER: Strohbehn GW
PROVIDER: S-EPMC9501784 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature